Citigroup Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 88.6%

Neg 88.6% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Neutral and lowers the price target from $44 to $41.